Transgenic mice have emerged as powerful tools in biologic drug discovery due to their unique ability to produce fully human antibodies. To date, the majority of fully human antibodies approved in the U.S. have been derived from one or another transgenic mouse platform.

Harbour BioMed' s biologic discovery programs are built on two proprietary transgenic mouse platforms designed to generate human therapeutic antibodies. These platforms hold broad potential for generating both conventional antibodies and the next-generation biologics that are fully human, affinity matured with excellent solubility and developability.

The transgenic mouse platforms include:

• H2L2 Harbour Mice^®, which generates traditional tetrameric antibodies consisting of two heavy chains and two light chains.
• HCAb Harbour Mice^®, a patented technology that produces novel heavy-chain-only antibodies, approximately half the size of a typical IgG. These antibodies retain IgG-like pharmacokinetic properties and Fc-domain functions without requiring additional engineering or humanization. The absence of a light chain minimizes issues related to light chain mispairing and heterodimerization. These features enable the development of products with attributes unattainable through conventional antibody platforms. In addition, the HCAb Harbour Mice^® platform supports the generation of various formats, including single-domain antibodies, bi- and multi-specifics, antibody-drug conjugates, CAR-Ts and VH domain-derived diagnostic or therapeutic products.

Both platforms demonstrate significant potential for generating promising therapeutic antibodies and accelerating drug discovery, as validated through partnerships with more than 140 academic and industry partners across over 380 projects. Among these, more than 20 molecules have advanced to the IND/clinical stage.